CD19/CD3 Bispecific T-cell Engagers as an Alternative for Safer B-Cell Depletion
Time: 2:00 pm
day: Day One Track B, PM
Details:
• Discussing clinical results of starting dose efficacy in B-cell lymphoma demonstrating B-cell depletion
• Highlighting the application of T-cell engagers to SLE and other autoimmune indications
